The new compound targets an enzyme overactive in chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome, cystic fibrosis and other diseases.
Nine centres within the hospital specialize in bone health, brain and behaviour, cancer, cystic fibrosis, heart, pain, image-guided care, genetic medicine, and transplantation.
Bacteria also form permanent, mostly lifelong, biofilms in the mucus-filled lungs of cystic fibrosis patients and are responsible for the chronic lung infections that lead to early death.
